Armed with debut financing of $44.5 million, Cambridge-based startup TCR2 Therapeutics is poised to advance its cell-based cancer therapies toward the clinic.

South Korean biotech Eutilex has seen a $21 billion KRW ($18.9 million) Series A funding boost as it looks to take its lead cancer med into midstage testing.

Shares in Voyager Therapeutics jumped 35% in after-hours trading on the back of interim data from an early trial of its Parkinson’s disease gene therapy.

Allaying concerns from some quarters that it wouldn’t be passed this year, and coming just one month after the presidential election, the 21st Century Cures…

AbbVie missed its survival targets in a new midstage trial of its PARP breast cancer candidate veliparib in combo with chemo, but the company is still hopeful…

Regulus has bulked up its pipeline with two new drug candidates due to start trials next year, as it tries to get lead hep C candidate back on track.

Neurimmune and TVM Capital Life Science have partnered to create and fund a single-asset biotech focused on amyotrophic lateral sclerosis.

Chinese researchers are publishing more than three times as many research papers on cancer topics than they were a decade ago.